How can sustainability and zero-carbon initiatives be achieved?
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
SAB Biotherapeutics has received both breakthrough and fast track designations from FDA for its lead antibody drug candidate for treating influenza.
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
The construction will expand Catalent’s clinical supply facility in Schorndorf, Germany.
Forecyte Bio has opened a new GMP facility in Shanghai just two months after its sister site in the United States.
The new site will include state-of-the-art cleanroom facilities, laboratories, R&D, and office spaces.
Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.
A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience.